-
ADVANCING COMPUTABLE OPERATIONAL DEFINITIONS WITH ONTOLOGY MAPPING AND SYNTHETIC DATA SIMULATION FOR MORE CONSISTENT REAL-WORLD EVIDENCE
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE HUMANISTIC BURDEN OF SJÖGREN’S DISEASE (SJD): A SYSTEMATIC LITERATURE REVIEW (SLR)
Mar 18, 2026, 21:38 PM -
ASSOCIATIONS BETWEEN SOCIAL MEDIA USAGE MOTIVATIONS, DEPENDENCY, AND OFFLINE SOCIAL OUTCOMES
Mar 18, 2026, 21:38 PM -
ASSESSING GENERIC PREFERENCE-BASED MEASURES FOR PROGRESSIVE SUPRANUCLEAR PALSY: A CONCEPT MAPPING APPROACH
Mar 18, 2026, 21:38 PM -
A MICROCOSTING STUDY OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) BASED ON REAL WORLD DATA FROM BRAZIL
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF VASOMOTOR SYMPTOMS AND DEPRESSION ON HEALTHCARE EXPENDITURES AMONG U.S. WOMEN
Mar 18, 2026, 21:38 PM -
EMPIRICAL TIME-SERIES ANALYSES IN THE PAST THREE DECADES 1991-2023 FOR IMMUNE THROMBOCYTOPENIA MEDICATIONS IN THE US MEDICAID PROGRAMS
Mar 18, 2026, 21:38 PM -
TEST-RETEST RELIABILITY OF CASE 1 BEST-WORST SCALING: EVIDENCE FROM RELATIVE ATTRIBUTE IMPORTANCE OF PREFERENCES FOR AI USE IN HEALTHCARE
Mar 18, 2026, 21:38 PM -
LONGITUDINAL ASSOCIATIONS OF CHEMOTHERAPY INDUCED SYMPTOM CLUSTERS WITH HEALTHCARE UTILIZATION AND MORTALITY AMONG PATIENTS WITH GASTROINTESTINAL CANCERS
Mar 18, 2026, 21:38 PM -
POPULATION HEALTH IMPACTS ASSOCIATED WITH NEW INDICATIONS: A CASE STUDY OF SGLT2-INHIBITORS
Mar 18, 2026, 21:38 PM -
ASSESSING THE IMPACT OF MISSINGNESS IN TREATMENT EFFECT MODIFIERS ON BIAS IN ANCHORED AND UNANCHORED MAIC AND STC
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF A COMPOSITE ENDPOINT IN HYPOPHOSPHATASIA TO OPTIMIZE COST-EFFECTIVENESS DEMONSTRATION
Mar 18, 2026, 21:38 PM -
AFFORDABILITY OF PEDIATRIC DRUGS THROUGH CHINA’S NATIONAL DRUG PRICE NEGOTIATION: 2017-2024
Mar 18, 2026, 21:38 PM -
UNDERSTANDING CEA CHARACTERISTICS ASSOCIATED WITH COST-SAVING FINDINGS
Mar 18, 2026, 21:38 PM -
DEVELOPMENT AND VALIDATION OF AN ALGORITHM TO IDENTIFY ASPIRIN USE FROM ELECTRONIC MEDICAL RECORDS AND CLAIMS DATA
Mar 18, 2026, 21:38 PM -
US MEDICINE PRICING POLICY CHANGES: IMPACT ON THE FULL BIOPHARMACEUTICAL INVESTMENT ECOSYSTEM
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS WITH REAL-WORLD DATA REUSING BRAZILIAN HEALTH SYSTEM DATABASES: A CASE STUDY IN BREAST CANCER
Mar 18, 2026, 21:38 PM -
ETHICAL AI DEPLOYMENT IN HEOR
Mar 18, 2026, 21:38 PM -
BREAKTHROUGH THERAPY (BT) AND FAST TRACK (FT) DESIGNATIONS IN NEW DRUG APPLICATIONS AND BIOLOGIC LICENSE APPLICATIONS (NDAS/BLAS) TO FDA’S CENTER FOR DRUG EVALUATION AND RESEARCH (CDER), 2013-2025
Mar 18, 2026, 21:38 PM -
CHOOSING PUBLIC LLMS AND AI AGENTS FOR PATIENT OUTCOMES RESEARCH: PRACTICAL PROS/CONS AND GOVERNANCE IMPLICATIONS
Mar 18, 2026, 21:38 PM
